Ardelyx 過去の業績
過去 基準チェック /06
Ardelyxは10.5%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで19.3%毎年増加している。売上は成長しており、年平均72.1%の割合である。
主要情報
10.5%
収益成長率
31.8%
EPS成長率
Biotechs 業界の成長 | 17.0% |
収益成長率 | 72.1% |
株主資本利益率 | -45.9% |
ネット・マージン | -28.8% |
前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It
Nov 24Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
Nov 14Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 03Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business
Oct 24Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?
Aug 25Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 07Ardelyx Faces Rising Challenges Despite Revenue Growth
Aug 05Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 04Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Jul 13Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge
Jul 05Ardelyx: Strong Execution, Fairly Valued
May 10Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 04Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)
May 03Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing
Apr 17Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Mar 13Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 24Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
Feb 20Ardelyx's XPHOZAH Still An Afterthought To The Pros
Jan 31Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement
Jan 10Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price
Jan 04Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt
Dec 14Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 03Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt
Jul 31Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now
Apr 17Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Mar 30Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Dec 14What To Expect For Ardelyx In The Coming Month
Oct 18収支内訳
収支内訳
Ardelyx の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Sep 24 | 252 | -73 | 230 | 0 |
30 Jun 24 | 210 | -65 | 198 | 0 |
31 Mar 24 | 159 | -66 | 161 | 0 |
31 Dec 23 | 124 | -66 | 134 | 0 |
30 Sep 23 | 134 | -27 | 106 | 0 |
30 Jun 23 | 83 | -56 | 92 | 0 |
31 Mar 23 | 63 | -66 | 84 | 0 |
31 Dec 22 | 52 | -67 | 77 | 0 |
30 Sep 22 | 9 | -114 | 75 | 0 |
30 Jun 22 | 5 | -135 | 73 | 0 |
31 Mar 22 | 4 | -153 | 75 | 0 |
31 Dec 21 | 10 | -158 | 69 | 0 |
30 Sep 21 | 11 | -151 | 66 | 0 |
30 Jun 21 | 12 | -125 | 56 | 0 |
31 Mar 21 | 13 | -105 | 43 | 0 |
31 Dec 20 | 8 | -94 | 33 | 0 |
30 Sep 20 | 8 | -85 | 29 | 0 |
30 Jun 20 | 8 | -91 | 28 | 0 |
31 Mar 20 | 6 | -91 | 26 | 0 |
31 Dec 19 | 5 | -95 | 24 | 0 |
30 Sep 19 | 3 | -103 | 23 | 22 |
30 Jun 19 | 0 | -104 | 22 | 40 |
31 Mar 19 | 0 | -100 | 23 | 56 |
31 Dec 18 | 3 | -91 | 24 | 0 |
30 Sep 18 | 45 | -53 | 24 | 64 |
30 Jun 18 | 44 | -50 | 24 | 62 |
31 Mar 18 | 44 | -53 | 23 | 66 |
31 Dec 17 | 42 | -64 | 23 | 75 |
30 Sep 17 | 0 | -106 | 23 | 150 |
30 Jun 17 | 0 | -114 | 21 | 134 |
31 Mar 17 | 0 | -117 | 21 | 114 |
31 Dec 16 | 0 | -112 | 19 | 94 |
30 Sep 16 | 0 | -98 | 18 | 0 |
30 Jun 16 | 0 | -87 | 17 | 0 |
31 Mar 16 | 18 | -50 | 15 | 0 |
31 Dec 15 | 24 | -30 | 14 | 39 |
30 Sep 15 | 30 | -16 | 12 | 0 |
30 Jun 15 | 38 | 2 | 11 | 0 |
31 Mar 15 | 29 | -6 | 9 | 0 |
31 Dec 14 | 32 | -3 | 7 | 0 |
30 Sep 14 | 34 | -4 | 6 | 1 |
30 Jun 14 | 33 | -5 | 5 | 3 |
31 Mar 14 | 31 | -7 | 5 | 6 |
31 Dec 13 | 29 | -7 | 4 | 0 |
質の高い収益: ARDXは現在利益が出ていません。
利益率の向上: ARDXは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ARDXは利益を出していないが、過去 5 年間で年間10.5%の割合で損失を削減してきた。
成長の加速: ARDXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: ARDXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。
株主資本利益率
高いROE: ARDXは現在利益が出ていないため、自己資本利益率 ( -45.85% ) はマイナスです。